MetaCap

Editas Medicine (EDIT) vs Kyverna Therapeutics (KYTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Editas Medicine (EDIT) has outperformed Kyverna Therapeutics (KYTX) over the past year, losing 32.2% versus a loss of 39.9%. Kyverna Therapeutics is the larger company by market cap ($269.3 million vs $253.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EDIT-32.23%KYTX-39.92%
+64%+9%-45%
Nov 21, 20251 yearNov 20, 2026
EDIT-77.99%KYTX-85.85%
+48%-26%-101%
Feb 5, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EDIT versus KYTX key metrics
MetricEDITKYTX
Share price$1.64$4.26
Market cap$253.12M$269.33M
1-day change-4.09%-2.52%
YTD return-20.00%-54.68%
1-year return-32.23%-39.92%
5-year return-94.93%—
EPS (TTM)$-0.54$-2.75
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$40.52M—
Revenue growth (YoY)+25.39%—
Net income (latest FY)$-160.06M$-161.31M
Operating margin-394.89%—
Net margin-395.01%—
52-week high$3.94$13.67
52-week low$1.63$4.18
Distance from 52-week high-58.38%-68.84%
Analyst consensusbuystrong_buy
Avg. price target upside+271.95%+613.62%
Average volume2.63M867.28K
Shares outstanding154.34M63.22M
Employees87172
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Editas Medicine

EDIT stock →

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 87 employees

About Kyverna Therapeutics

KYTX stock →

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 172 employees

EDIT vs KYTX FAQ

Which is bigger, Editas Medicine or Kyverna Therapeutics?

Kyverna Therapeutics (KYTX) is larger, with a market capitalization of $269.33M compared with $253.12M for Editas Medicine (EDIT).

Which stock has performed better over the past year, EDIT or KYTX?

EDIT returned -32.23% over the past 12 months, compared with -39.92% for KYTX (price return, excluding dividends). Past performance does not predict future results.

Are Editas Medicine and Kyverna Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons